MabGenesis株式会社 Stock: price and insider trades · Japan
MabGenesis株式会社: what insiders have been doing
Every trade that managers of MabGenesis株式会社 disclose to EDINET (Japan FSA) is tracked on this page. The last twelve months, up to 6 November 2026, brought 11 filings signed by 6 insiders.
Only sales appear on the open market, 1 sale in all totalling €866k, filed by 1 insider. At €866k, the sale published on 6 November 2026 by Long Black Partners Co., Ltd. is the largest of the period (2.6% of market cap).
Typically, a trade is published a median of 3 days after it takes place. Until a filing is published, the market cannot know about the trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 11 filings in twelve months, the company is more active than the median of 3 filings across the 3,223 companies we follow on the same exchange. Over the whole record (from 2026), the tally stands at no purchases and 1 sale.
These figures are compiled from regulatory filings published by EDINET (Japan FSA). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleThis score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
- ShareXTKSEDINET:S100ZCG1
- ShareXTKSEDINET:S100Z8O1
- 200,000 shares@ JP¥763.602.61% mcap100.0% of flowShareXOFFEDINET:S100Z8O1:T1
- ShareXTKSEDINET:S100ZAOU
- ShareXTKSEDINET:S100ZC67
- ShareXTKSEDINET:S100ZBPL
- ShareXTKSEDINET:S100ZBQ5
- ShareXTKSEDINET:S100ZBMA
- ShareXTKSEDINET:S100ZBLH
- ShareXTKSEDINET:S100ZAVF
- ShareXTKSEDINET:S100ZAVE
11 of 11 declarations
About MabGenesis株式会社
MabGenesis is a company listed on the XTKS market. It specializes in the development of innovative therapies for the treatment of genetic diseases.
